About: Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine
Creator	Kariwa, Hiroaki Baek, Min-Won Kim, Dong-Jae Lee, Byoung-Hee Lee, Hyun-Kyoung Na, Yi-Rang Park, Jae-Hak Park, Sung-Hoon Mai, Le Kumar Dutta, Noton Mazumdar, Kaushiki
Source	Elsevier; Medline; PMC
abstract	It is believed today that nucleocapsid protein (N) of severe acute respiratory syndrome (SARS)-CoV is one of the most promising antigen candidates for vaccine design. In this study, three fragments [N1 (residues: 1–422); N2 (residues: 1–109); N3 (residues: 110–422)] of N protein of SARS-CoV were expressed in Escherichia coli and analyzed by pooled sera of convalescence phase of SARS patients. Three gene fragments [N1 (1–1269 nt), N2 (1–327 nt) and N3 (328–1269 nt)—expressing the same proteins of N1, N2 and N3, respectively] of SARS-N were cloned into pVAX-1 and used to immunize BALB/c mice by electroporation. Humoral (by enzyme-linked immunosorbent assay, ELISA) and cellular (by cell proliferation and CD4(+):CD8(+) assay) immunity was detected by using recombinant N1 and N3 specific antigen. Results showed that N1 and N3 fragments of N protein expressed by E. coli were able to react with sera of SARS patients but N2 could not. Specific humoral and cellular immunity in mice could be induced significantly by inoculating SARS-CoV N1 and N3 DNA vaccine. In addition, the immune response levels in N3 were significantly higher for antibody responses (IgG and IgG1 but not IgG2a) and cell proliferation but not in CD4(+):CD8(+) assay compared to N1 vaccine. The identification of antigenic N protein fragments has implications to provide basic information for the design of DNA vaccine against SARS-CoV. The present results not only suggest that DNA immunization with pVax-N3 could be used as potential DNA vaccination approaches to induce antibody in BALB/c mice, but also illustrates that gene immunization with these SARS DNA vaccines can generate different immune responses.
has issue date	2008-06-15(xsd:dateTime)
bibo:doi	10.1016/j.imlet.2008.03.003
bibo:pmid	18440652
has license	no-cc
sha1sum (hex)	6f6397ff2cc785076b76b648693ac358b60da6ae
schema:url	https://doi.org/10.1016/j.imlet.2008.03.003
resource representing a document's title	Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine
has PubMed Central identifier	PMC7112843
has PubMed identifier	18440652
schema:publication	Immunol Lett
resource representing a document's body	covid:6f6397ff2cc785076b76b648693ac358b60da6ae#body_text
is schema:about of	named entity 'DNA VACCINE' named entity 'patients' named entity 'SARS-CoV' named entity 'immunization' named entity 'responses' named entity 'Results' named entity 'specific' named entity 'target' named entity 'GENE' named entity 'STUDY' named entity 'ANTIGEN' named entity 'NUCLEOCAPSID PROTEIN' named entity 'ONE OF' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'SERA' named entity 'USING' named entity 'INDUCED' named entity 'CELLULAR' named entity 'ELISA' named entity 'CELL PROLIFERATION' named entity 'ELECTROPORATION' named entity 'ADDITION' named entity 'PROTEINS' named entity 'PATIENTS' named entity 'ASSAY' named entity 'VACCINE' named entity 'SARS' named entity 'SARS-COV' named entity '110' named entity 'VACCINE DESIGN' named entity 'BASIC' named entity 'HIGHER' named entity 'THESE' named entity 'CD4' named entity 'BASED' covid:arg/6f6397ff2cc785076b76b648693ac358b60da6ae named entity 'POTENTIAL' named entity 'DNA IMMUNIZATION' named entity 'IGG2A' named entity 'COMPARED' named entity 'IMMUNITY' named entity 'N PROTEIN' named entity 'TO PROVIDE' named entity 'IMMUNE RESPONSE' named entity 'REACT' named entity 'INDUCE' named entity 'ANTIBODY' named entity 'DNA VACCINE' named entity 'DNA VACCINATION' named entity 'COULD BE' named entity 'RESPONSES' named entity 'CONVALESCENCE' named entity 'PROTEIN ' named entity 'SARS' named entity 'INFORMATION' named entity 'RECOMBINANT' named entity 'RESULTS' named entity 'SITE OF' named entity 'NUCLEOCAPSID' named entity 'TARGET SITE' named entity 'PHASE' named entity 'GENERATE' named entity 'ANALYZED' named entity 'POTENTIAL' named entity 'FRAGMENTS' named entity 'DNA VACCINES' named entity 'EPITOPE' named entity 'SUGGEST' named entity 'BALB' named entity 'SPECIFIC ANTIGEN' named entity 'USED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software